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Association of Tricuspid Annular Plane Systolic Excursion with
Survival Time in Boxer Dogs with Ventricular Arrhythmias
B.M. Kaye, K. Borgeat, P.F. M~otsk€ula, V. Luis Fuentes, and D.J. Connolly
Background: Tricuspid annular plane systolic excursion (TAPSE) is a useful estimate of right ventricular function in
humans. Reference intervals for dogs have been generated, but the value of measuring TAPSE in other diseases, or investigat-
ing the association between TAPSE and outcome, is unknown.
Hypothesis: TAPSE is lower in Boxer dogs with ≥50 VPCs/24 h on Holter than in dogs with fewer ventricular ectopics,
and lower TAPSE is associated with a shorter survival time.
Animals: Fifty Boxer dogs that presented for investigation of syncope or suspected arrhythmogenic right ventricular car-
diomyopathy (ARVC) at a veterinary teaching hospital (2004–2011).
Methods: Retrospective study. Clinical records, Holter, and echocardiographic data were reviewed. TAPSE was measured
in a blinded manner on stored echocardiographic cine-loops using anatomic M-mode. Outcome information was obtained
and death was classified as cardiac or noncardiac. Survival analysis was performed using Kaplan-Meier curves and Cox pro-
portional hazards models.
Results: TAPSE was lower in Boxers with ≥50 VPCs/24 h (13.9  4.04 mm) than Boxers with <50 VPCs/24 h
(16.8  3.21 mm; P < .001). TAPSE <15.1 mm was associated with shorter cardiac survival time in all dogs (P = .004) and
also in dogs without left ventricular dysfunction (P = .035). When controlling for other variables, including ventricular tachy-
cardia on Holter and left ventricular systolic dysfunction, multivariable analysis showed that TAPSE remained an indepen-
dent predictor of time to cardiac death (HR >4.09, 95%CI 1.15–16.9, P < .029).
Conclusions and Clinical Importance: TAPSE offers prognostic value for Boxer dogs, including those with apparently
normal systolic function and ≥50 VPCs/24 h on Holter analysis.
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Introduction
Arrhythmogenic right ventricular cardiomyopathy(ARVC) is a primary myocardial disease character-
ized by fibro-fatty infiltration of the right, and occasion-
ally left, ventricle.
The diagnosis of ARVC in humans is based upon a
combination of genetic screening, family history, ambu-
latory electrocardiography (Holter), and the detection
of right ventricular adipose tissue on cardiac magnetic
resonance imaging (cMRI).1 There is an extensive litera-
ture describing the genetic, clinical, echocardiographic,
and electrophysiologic characteristics of ARVC in
Boxer dogs.2–6
There are several prognostic indicators for Boxers
dogs with ARVC. Shorter survival times are associated
with echocardiographic evidence of left ventricular (LV)
systolic dysfunction,5,7 increased frequency and com-
plexity of VPCs, including ventricular tachycardia (VT),
and polymorphic VPCs.7
In human medicine, right ventricular (RV) function is
commonly assessed by measurement of tricuspid annu-
lar plane systolic excursion (TAPSE) using M-mode
echocardiography.8–11 TAPSE is a quantitative estimate
of longitudinal RV shortening. It does not account for
the radial and circumferential motion of the RV myo-
cardial wall, but physiologic studies in humans have
shown that RV shortening is greater longitudinally than
radially and torsion contributes less to RV than LV
output.12 TAPSE was significantly correlated with RV
ejection fraction in validation studies against the gold
standard of radio-nuclide angiography,13 and reduced
TAPSE is associated with a worse outcome in people
with congenital heart disease, pulmonary hypertension,
acute symptomatic pulmonary embolism, hypertrophic
cardiomyopathy, and ARVC.8,14–16 Several studies have
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also reported a correlation in humans between TAPSE
and echocardiographic measures of LV systolic func-
tion,17 illustrating the interdependence between the left
and right heart.
Assessing RV function has received recent attention
in animals. The index of myocardial performance (or
TEI index) has been evaluated in Boxer dogs with
ARVC, and measurements suggested worse global myo-
cardial performance in affected dogs, independent of
body weight and heart rate variability.18 Reference
intervals for TAPSE in normal dogs of various breeds
and body weights have been derived.19 In the same
study, dogs with pulmonary hypertension had lower
TAPSE than dogs without pulmonary hypertension. In
addition, TAPSE is easily obtained and repeatable.1
This suggests that TAPSE could be a practical and clin-
ically useful measurement in RV dysfunction in dogs, as
has already been reported in humans. To the authors’
knowledge, the association between TAPSE and out-
come has not been reported in dogs for any disease pro-
cess.
The aim of this study was to evaluate the clinical util-
ity of TAPSE in a cohort of Boxer dogs presented for
evaluation of syncope or suspected ARVC. We hypoth-
esized that TAPSE would be lower in dogs with ≥50
VPCs/24 h on Holter analysis compared to dogs with
<50 VPCs/24 h. We also hypothesized that lower
TAPSE would be significantly associated with a shorter
time to an end-point of cardiac death.
Materials and Methods
Dogs and Clinical Data
Records of client-owned Boxer dogs that presented to a veteri-
nary teaching hospital for investigation of suspected ARVC or
other clinical signs of cardiac disease (2004–2011) were retrospec-
tively reviewed. All dogs were assessed under the supervision of a
Board-certified cardiologist. Dogs were eligible for inclusion if they
had at least 1 Holter recording with a minimum of 19 hours of
valid data and an echocardiographic examination within 1 month
of Holter available for review. Dogs with documented congenital
heart disease were excluded from the study, including those with
aortic blood flow velocities ≥2.25 m/s.20 Dogs were also excluded
if stored echocardiographic images were not suitable for measure-
ment of TAPSE by off-line measurement software, or if they had a
concurrent diagnosis of a potentially life-limiting disease, such as
malignant neoplasia. All Boxer dogs in this study were referred to
the cardiology service of the Royal Veterinary College for the fur-
ther assessment of clinical signs or physical exam findings includ-
ing collapse or arrhythmia and were not screened for ARVC as
part of a breed club program.
Baseline clinical details obtained from medical records at the
time of the first Holter recording included age, sex, body weight,
and presenting clinical signs, defined as: absent; a history of syn-
cope, episodic weakness/collapse that was believed to be consistent
with syncope; or the presence/absence of congestive heart failure
(CHF) at or before initial presentation. CHF was considered pres-
ent if radiographic evidence of cardiogenic pulmonary edema was
detected or if the dog had clinical evidence of ascites with either
concurrent jugular distension/pulsation or hepatic congestion, with
a clinical response to diuretic treatment. Medication that dogs
were receiving at the time of presentation was also documented.
Information on survival was obtained via several means; com-
plete medical records, questionnaires mailed to owners, and tele-
phone contact with clients and referring veterinarians.
Documented outcome data included whether the dog was alive or
dead, the date of death or euthanasia, and whether the death was
cardiac related. Cardiac death was defined as death or euthanasia
associated with clinical signs attributable to cardiac disease
(uncontrolled CHF, worsening CHF, or unacceptable increase in
the frequency of syncope) or an unexpected death without appar-
ent clinical signs during the preceding 24-hour period. Necropsy
data were not available.
Echocardiography
Echocardiographya was performed in unsedated dogs and all
echocardiographic images were acquired by a cardiology diplomate
or cardiology Resident under direct supervision. For calculation of
left atrial to aortic root ratio (LA/Ao), diameters of the left atrium
(LA) and aorta were measured using 2D echocardiography in a
right parasternal short axis view of the heart base, from the first
frame after aortic valve closure (end-systolic).21 M-mode echocar-
diography was used to measure (leading-edge to leading-edge) LV
internal diameters in systole (LVIDs) and diastole, and to calculate
fractional shortening (FS%).22,23 Spectral Doppler echocardiogra-
phy was used to measure aortic outflow velocity from a subcostal
window. Left ventricular systolic dysfunction (SD) was deemed
present where: LVIDs>35 mm,5,7 FS%<25%, or ejection fraction
(EF%) <50%.7 EF% was measured by the Modified Simpson’s
method.24
All TAPSE measurements were performed by a single observer
(BK), blinded to the dog outcome. TAPSE was measured using
2D anatomic M-mode on a suitable left apical 4-chamber image as
previously described in dogs.19 The initial measurement was taken
at the onset of ventricular systole, defined as the onset of the QRS
complex on simultaneous ECG. Cardiac cycles within 1 beat of an
atrial or ventricular premature complex were not considered suit-
able for measurement. Where possible, 3 consecutive measure-
ments of TAPSE were performed and the mean value recorded.
Intraobserver variability in TAPSE measurement was assessed
using images from a randomly selected subset of 10 dogs, each
measured 5 times. Coefficient of variation (CV) was calculated and
defined as acceptable if CV<10%.
Holter ECG
Holter records were reviewed by a single operator (PM),
blinded to outcome. Dogs were dichotomized into 2 groups based
on Holter analysis: ≥50 VPCs/24 h and <50 VPCs/24 h. Ventricu-
lar tachycardia, defined as >3 consecutive VPCs with a sustained
heart rate >100 beats/min, was also recorded as present/absent.7
Where multiple Holter ECGs were performed, the first Holter,
which was placed within 1 month of echocardiography, was used
for analysis.
Statistical Analysis
Statistical analyses were performed by commercially available
software.bc Normality was determined graphically and using the
Shapiro-Wilk test. Normally distributed data were represented as
mean (standard deviation) and compared using an independent
samples t-test. Nonnormally distributed data were represented as
median (range) and compared using a Mann-Whitney U-test. Con-
tinuous variables were assessed for linear association using a Pear-
son’s correlation test.
Survival analysis was performed using an end-point of cardiac
death. Animals dying of noncardiac disease or alive at the end of
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the study period were right-censored. Continuous variables were
explored by division into groups based on quartiles, and the effect
of these variables on survival was evaluated using Kaplan-Meier
survival analysis and Log-rank tests. Where 1 or more groups had
disproportionately different hazards to the others, these variables
were presumed to exhibit a threshold effect and were included in
Cox models as categorical variables using a cut-off established by
the exceptional quartile/s. For example, LA:Ao was included in
the analysis dichotomized either side of the median value.
Univariable time-to-event models were constructed using Cox
proportional hazards analysis. Factors where P < .2 in the univari-
able analysis were included in the multivariable analysis. Multivar-
iable Cox proportional hazards analysis was performed in a
forward stepwise manner. The assumptions of Cox proportional
hazards were tested using log cumulative hazard plots and Schoen-
feld residuals. Overall model fit was evaluated using Cox-Snell
residuals. Statistical significance was set at the 5% level.
Results
Population
Eighty-one eligible Boxer dogs were evaluated for
ARVC over the period (2004–2011). Thirty-one were
excluded because of inadequate quality, poor alignment
of echocardiographic images for measurement of
TAPSE, or both; leaving 50 dogs with complete data
on echocardiography, 24 hours Holter and outcome
where TAPSE could be appropriately measured.
Fifty percent of the population studied was male.
Median age was 6.0 years (0.5–12.5 years) and mean
weight was 30.2 kg (6.2 kg). Males were significantly
heavier (34.2  4.7 kg) than female dogs
(26.3  4.7 kg; P < .001). Syncope was the primary
presenting sign in 39/50 (78%) dogs. Exactly, 7/50
(14%) dogs presented with or had a history of CHF.
Medication histories were available for all Boxer dogs
(Table 1). Thirty-five dogs were not receiving any medi-
cation, 7 dogs were receiving antiarrhythmic medica-
tion, either alone or in combination with other
therapeutics, and 10 dogs were receiving a diuretic,
either alone or in combination with other therapeutics.
Fifty-six percentage (28/50) of Boxer dogs had ≥50
VPCs on 24 hour Holter analysis. Of the remaining 22
dogs with <50 VPCs, 11 (50%) had echocardiographic
evidence of systolic dysfunction. Of the 28 dogs with
≥50 VPCs, 20 (71%) had systolic dysfunction (Table 2).
Among dogs presenting with syncope, ≥50 VPCs were
detected in 22/39 (56%) cases. Six dogs that had ≥50
VPCs, had no history of syncope. Dogs with ≥50 VPCs
were significantly older (7.7 years, range 0.5–12.5 years)
than those with <50VPCs (4.9 years, range 0.9–10 years;
P = .046). There was no significant difference in weight
or sex between groups (Table 2).
Tricuspid Annular Plane Systolic Excursion
A minimum of 2 consecutive TAPSE measurements
was obtained in 45/50 (90%) of dogs, and 3 consecutive
TAPSE measurements were achievable in 27/50 (54%)
of stored echocardiographic studies. Intraobserver vari-
ability of TAPSE measurement was 8%. Mean TAPSE
for the entire population was 15.2 mm (3.9 mm).
TAPSE exhibited a weak negative correlation with both
absolute weight (r = 0.324, P = .022) and weight
scaled to the 1/3 power (r = 0.295, P = .038; Fig 1).22
There was no significant difference in TAPSE between
genders (P = .39). Because correlation between TAPSE
and weight was weak and unlikely to be clinically rele-
vant (Fig 1), TAPSE was evaluated as an absolute mea-
surement, rather than an indexed value. Dogs
diagnosed with ≥50 VPCs/24 h had a significantly lower
TAPSE (13.9  4.04 mm) than the <50 VPCs/24 h
group (16.8  3.21 mm; P = .008, Table 2). TAPSE
demonstrated weak to moderate correlation at the 5%
significance level with the following variables: ejection
fraction (r = 0.354, P = .017), fractional shortening
(r = 0.424, P = .002), and LA:Ao (r = 0.448,
P = .002). Dogs with LV systolic dysfunction had sig-
nificantly lower TAPSE (14.1  3.78 mm) than those
with normal LV systolic function (16.8  3.73 mm;
P = .02). Also, dogs with detectable VT on Holter had
lower TAPSE (12.9  3.21 mm) than those without VT
(16.1  3.87 mm; P = .008; Fig 2).
Survival Analysis
At the end of the study period, 26/50 (52%) Boxer
dogs were dead; 20 dogs (40%) had suffered a cardiac
death, 6 (12%) dogs died because of noncardiac causes,
20 (40%) remained alive, and 4 (8%) dogs were lost to
follow-up. Median survival time to cardiac death for all
dogs was 440 days (6–2,083 days).
The presence of ≥50 VPCs on 24 hour Holter (yes
versus no) and the presence of systolic dysfunction
(present versus absent) were included in the Cox pro-
portional hazards analysis as separate variables. The
results of univariable Cox proportional hazards analysis
are shown in Table 3. Lower TAPSE (<15.1 mm; cut-
off based upon a threshold effect seen when dichotomiz-
ing either side of median TAPSE value for the whole
population, as described above) was significantly associ-
ated with a shorter time to cardiac death (hazard ratio
6.1, 95% confidence intervals 1.8–21; P = .004; Fig 3).
In the 19 dogs without echocardiographic evidence of
LV systolic dysfunction, TAPSE remained significantly
Table 1. Medical treatment received by Boxer dogs at
the time of examination.
Medication Number Receiving
None 35
Furosemide 10
Pimobendan 8
Benazapril 5
Spironolactone 4
Enalapril 4
Digoxin 4
Sotalol 3
Amiloride 1
Amiodarone 1
Hydrochlorothiazide 1
Mexiletine 1
Phenobarbitone 1
Ramipril 1
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associated with a shorter time to cardiac death
(P = .035; Fig 4).
Variables carried forward to the multivariable Cox
analysis were: TAPSE (<15.1 mm), weight (continuous
variable), presence of ≥50VPCs on 24 hour Holter, LV
systolic dysfunction, LA:Ao ratio (≥1.76), CHF (yes)
and VT (yes). Because 20 cardiac deaths were recorded,
multivariable models were limited to a maximum of 2
factors. To avoid violation of the assumptions of Cox
proportional hazards analysis, we chose not to include
the combination of 2 echocardiographic variables (spe-
cifically LA size and LV systolic dysfunction) in the
same model.
Multivariable analysis (Table 4) suggested that
TAPSE was associated with a shorter time to cardiac
death, independent of the presence of CHF, systolic
dysfunction, and detectable VT. Weight and age each
lost statistical significance when included with TAPSE
<15.1 mm, which remained significantly associated with
a shorter survival time.
Discussion
Our results show that measurement of TAPSE in
Boxer dogs with suspected ARVC provides useful prog-
nostic information, in addition to a 24-hour Holter
recording. Multivariable analysis showed that TAPSE
<15.1 mm remained significantly associated with a
shorter time to an end-point of cardiac death, even when
controlling for the presence of CHF, Holter detection of
VT, and echocardiographic evidence of LV systolic dys-
function. This is similar to findings in humans, where an
absolute TAPSE measurement <18.1 mm is associated
with a greater incidence of cardiac mortality in dogs with
heart failure.25 Although our data suggested that TAPSE
exhibited weak to moderate correlation with echocardio-
graphic estimates of LV systolic function, when dogs
with identifiable LV systolic dysfunction were excluded
from survival analysis, dogs with TAPSE <15.1 mm still
had a significantly shorter survival time than those with
higher TAPSE. Despite a small sample size and low
event rate in this group of dogs, our analysis did show a
significant difference, suggesting that this is a genuine
finding which merits further prospective study and vali-
dation in a larger cohort of Boxer dogs.
Table 2. Characteristics of the 50 Boxer dogs included in survival analysis: tricuspid annular plane systolic
excursion (TAPSE) and age at diagnosis were significantly different between groups. Normally distributed data are
represented mean ( standard deviation) and nonnormally distributed data are represented median (range).
Factor Non-ARVC: <50 VPCs on Holter) ARVC: ≥50 VPCs on Holter P Value
Number 22 28 –
Age (years) 4.9 (0.9–10.0) 7.7 (0.5–12.5) .046
Male: number (%) 9 (41%) 16 (57%) .39
Weight (kg) 28.8 (5.57) 31.4 (6.48) .14
Systolic dysfunction: number (%) 11 (50%) 20 (71%) .079
TAPSE (mm) 16.8 (3.21) 13.9 (4.04) .008
Fig 1. Scatter plots to show correlation between tricuspid annular
plane systolic excursion (TAPSE) and weight. Both absolute
weight (r = 0.324, P = .022) and weight scaled to the 1/3 power
(r = 0.295, P = .038)22 exhibited a weak, negative correlation
with TAPSE.
Fig 2. Scatter plots to illustrate the association of tricuspid
annular plane systolic excursion (TAPSE) with Holter variables.
TAPSE was significantly lower in dogs with ventricular tachycar-
dia (VT) detected on Holter ECG (P = .008).
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This study indicates that measurement of TAPSE is
straightforward and repeatable, with acceptable intraob-
server variability. However, during our inclusion of
dogs for this study, we discovered that 31/81 echocar-
diographic studies (38%) from suitable Boxer dogs were
excluded from analysis because of poor alignment or
image quality. This is at least in part a consequence of
the retrospective nature of this study using previously
acquired images. Prospective acquisition of suitable
images for TAPSE measurement was successfully per-
formed in 80 dogs over a wide range of body weights
and breeds in 1 recent study.1 That said, the acquisition
of appropriate images for measurement of TAPSE
might be prone to error if performed by an inexperi-
enced operator or in a poorly compliant dog.
Our results showed a weak negative correlation
between TAPSE and weight (absolute and scaled to the
1/3 power, Fig 1). Interestingly, a previous study
reported a positive correlation in a population of nor-
mal dogs of different breeds and a greater weight
range.22 This discrepancy between our data and theirs is
difficult to explain but might reflect the different popu-
lations used and in particular the fact that our popula-
tion consisted of dogs with myocardial disease. Our
study design does not allow us to explain why heavier
dogs in this population might have had lower TAPSE
values. Despite this correlation reaching statistical sig-
nificance, we elected to analyze TAPSE as an absolute
measurement rather than indexing for body weight as
previously described.22 This decision was made because
the correlation was weak and the scatter plots of this
data suggested that it was unlikely to be clinically rele-
vant. We also felt that an absolute measurement would
have greater clinical utility than a calculated indexed
value. We believe that this is justified in Boxer dogs,
because the range of body sizes among dogs of 1 breed
is more limited than that evaluated by a previous study
across different breeds.22 Another study used a single
cut-off value of LVIDs >35 mm to quantify systolic
dysfunction in Boxers,5 and similar single measurements
are commonly used among veterinary cardiologists
without indexing to a measure of body size.5,8,10,26 Body
weight was also not significantly different between the
≥50 and <50 VPCs/24 h groups in our study, and
although body weight was significantly associated with
outcome at the univariable level, this association did
not remain present at the multivariable level.
There is currently no definitive consensus among vet-
erinary cardiologists as to how ARVC in Boxer dogs is
best diagnosed.3,7,27–29 We acknowledge that our cut-off
Fig 3. Kaplan-Meier curve to show the effect of tricuspid annular
plane systolic excursion (TAPSE) on survival time to cardiac
death. Boxer dogs with TAPSE below the population median
(<15.1 mm) had a significantly shorter survival time to cardiac
death than those with higher TAPSE measurements (P < .001).
Fig 4. Kaplan-Meier curve to show the effect of tricuspid annular
plane systolic excursion (TAPSE) on survival time to cardiac death
in dogs without echocardiographic evidence of left ventricular sys-
tolic dysfunction. Dogs with TAPSE below the population median
(<15.1 mm) had a significantly shorter survival time to cardiac
death than those with higher TAPSE measurements (P = .035).
Table 3. Results of univariable Cox proportional haz-
ards analysis to evaluate factors associated with a
shorter time to cardiac death.
Factor
Hazard
Ratio
95% Confidence
Intervals P Value
TAPSE (≥15.1 mm) Ref.
TAPSE (<15.1 mm) 6.1 1.8–21.0 .004
Weight: continuous
per +1 kg
1.1 1.0–1.2 .028
Sex: Male = No Ref.
Sex: Male = Yes 1.8 0.7–4.5 .23
ARVC diagnosis = no Ref.
ARVC diagnosis = yes 7.3 2.1–25.5 .002
LV systolic
dysfunction = No
Ref.
LV systolic
dysfunction = Yes
5.9 1.3–26.1 .019
LA:Ao (<1.76) Ref.
LA:Ao (≥1.76) 2.4 0.9–6.8 .088
Presence of CHF = No Ref.
Presence of CHF = Yes 5.7 2.1–16.0 .001
Presence of VT = No Ref.
Presence of VT = Yes 5.6 2.2–14.2 <.001
TAPSE, tricuspid annular plane systolic excursion; VPCs,
ventricular premature complexes; LV, left ventricle; LA, left
atrium; Ao, aorta; CHF, congestive heart failure; VT, ventricular
tachycardia.
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value of 50 VPCs on 24-hour Holter analysis is a low
threshold for ARVC diagnosis. However, it is more
likely to include Boxer dogs that are in the early stage
of the disease. Evidence suggests that arrhythmias may
precede the development morphologic abnormalities in
dogs with ARVC.30 Therefore, in Boxer dogs that pres-
ent for investigation of clinical signs, our TAPSE find-
ings should provide clinicians with a more powerful
prognostic indicator of survival, irrespective of VPC
number. Our results suggest that TAPSE is a clinically
useful measurement, giving additional relevant informa-
tion whichever cut-off value the clinician should choose
to diagnose ARVC.
Day-to-day variation of VPC number on Holter can be
>80% in dogs with ARVC,31 and there can be significant
annual variation in the number of VPCs detected.3 Some
dogs with a diagnosis of ARVC have fewer than 50 VPCs
the year after a Holter showing ≥300 VPCs, despite
receiving no antiarrhythmic medication whatsoever.3 It
would therefore be interesting to evaluate TAPSE in a
longitudinal fashion in a similar cohort of dogs.
Other limitations of this study are typical for any ret-
rospective data analysis. Boxer dogs had diagnostic tests
and treatment provided based upon individual decision
making of the primary clinician managing each case at
the time it is presented. Differences in treatment and
diagnostic protocol could not be accounted for in our
analysis. An inability to obtain 3 consecutive TAPSE
measurements in 46% of stored images was the result
of frequent ventricular arrhythmias in many of the
Boxer dogs and could have impacted on the accuracy
of the TAPSE measurement. However despite this,
TAPSE remained significant following multivariable
analysis when applied to affected dogs in a working
clinical environment. Misclassification of clinical status,
such as the presence/absence of CHF, and outcome
(cardiac versus noncardiac death) are possible, despite
robust criteria. A further limitation is that these dogs
were placed on multiple different treatment protocols,
which may have altered over time as their disease pro-
gressed. The study was not designed to assess the effect
of medication on TAPSE.
Because of its complex geometry with dense trabecula-
tion and load dependence, the RV is challenging to
measure accurately using echocardiography.12 Despite
this, TAPSE appears to be a reasonable, indirect estimate
of RV function and was significantly associated with out-
come in our study. As further imaging techniques are
studied to evaluate the right heart, including evaluating
RV myocardial strain or RV geometrical changes by 3D
ultrasound technology and MRI techniques, more accu-
rate measures of RV function may be validated for use in
dogs. However, TAPSE has the benefit of accessibility to
a greater number of practitioners, being simple to per-
form with standard echocardiographic equipment and an
appropriate level of operator experience.
In conclusion, our results indicate that TAPSE
<15.1 mm in Boxer dogs with ≥50 VPCs/24 h on Holter
analysis is associated with a shorter time to cardiac
death, irrespective of the presence of CHF, echocardio-
graphic evidence of LV systolic dysfunction, and Holter
detection of VT. This easy to obtain and repeatable
measurement therefore gives the clinician valuable prog-
nostic information in addition to that provided by Hol-
ter analysis alone.
Footnotes
1 Visser LC, Scansen BA, Brown NV, et al. ACVIM Forum
Research Abstracts Program. J Vet Intern Med. 2014;28:1000.
(abstract C.2).
a Vivid 7 with EchoPac off-line measurement software, GE
systems, Hatfield, United Kingdom.
b IBM SPSS Statistics Version 21; for Windows 7, IBM (UK)
Ltd, Portsmouth, UK.
c GraphPad Prism Version 6.0; for Windows 7, GraphPad Soft-
ware Inc. Sandiego, CA, USA.
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Table 4. Results of multivariable Cox proportional hazards analysis, performed to evaluate the association of
tricuspid annular plane systolic excursion (TAPSE) on time to cardiac death when controlling for the effect of other
measured variables. Reduced TAPSE lost statistical significance when patients had R-on-T phenomenon detected on
Holter, but did demonstrate a significant association with shorter survival time when controlling for the presence of
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